ABG
Ally Bridge Group Portfolio holdings
AUM
$114M
This Quarter Return
+9.43%
1 Year Return
+41.64%
3 Year Return
+246.39%
5 Year Return
–
10 Year Return
–
AUM
$168M
AUM Growth
+$168M
(-6.7%)
Cap. Flow
-$16.8M
Cap. Flow
% of AUM
-10.02%
Top 10 Holdings %
Top 10 Hldgs %
55.87%
Holding
32
New
10
Increased
1
Reduced
13
Closed
7
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$11.6M |
| 2 |
Legend Biotech
LEGN
|
$8.64M |
| 3 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$8.23M |
| 4 |
Disc Medicine
IRON
|
$7.5M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$7.39M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$11.9M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$9.19M |
| 3 |
Insmed
INSM
|
$8.11M |
| 4 |
Dianthus Therapeutics
DNTH
|
$6.51M |
| 5 |
Olema Pharmaceuticals
OLMA
|
$6.33M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Soleno Therapeutics
SLNO
$3.6B
| $11.7M | 6.96% | 286,162 -50,324 | -15% | -$2.05M |
|
|
2
Sarepta Therapeutics
SRPT
$1.78B
| $11.6M | 6.92% | +73,500 | New | +$11.6M |
|
3
Geron
GERN
$893M
| $11.6M | 6.91% | 2,736,663 -23,834 | -0.9% | -$101K |
|
4
Merus
MRUS
$4.98B
| $10.3M | 6.16% | 174,844 -81,084 | -32% | -$4.8M |
|
|
5
Insmed
INSM
$28.8B
| $8.64M | 5.15% | 129,000 -121,000 | -48% | -$8.11M |
|
|
6
Legend Biotech
LEGN
$6.41B
| $8.64M | 5.15% | +195,000 | New | +$8.64M |
|
|
ALMS
7
Alumis Inc. Common Stock
ALMS
$479M
| $8.23M | 4.9% | +618,750 | New | +$8.23M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $8.15M | 4.86% | 75,638 -85,312 | -53% | -$9.19M |
|
|
9
Disc Medicine
IRON
$2.07B
| $7.5M | 4.47% | +166,500 | New | +$7.5M |
|
|
10
Day One Biopharmaceuticals
DAWN
$769M
| $7.39M | 4.4% | +536,095 | New | +$7.39M |
|
11
MindMed
MNMD
$676M
| $6.96M | 4.15% | 965,426 -36,026 | -4% | -$260K |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $6.6M | 3.93% | 169,369 -140,000 | -45% | -$5.46M |
|
13
Praxis Precision Medicines
PRAX
$958M
| $6.34M | 3.78% | 153,379 -6,107 | -4% | -$253K |
|
14
Kura Oncology
KURA
$686M
| $6.32M | 3.76% | 306,762 -58,282 | -16% | -$1.2M |
|
|
AVDL
15
Avadel Pharmaceuticals
AVDL
$1.43B
| $6.05M | 3.6% | 430,245 -116,791 | -21% | -$1.64M |
|
|
LBPH
16
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $5.92M | 3.53% | 218,981 -51,578 | -19% | -$1.39M |
|
17
CG Oncology
CGON
$2.04B
| $5.52M | 3.29% | 174,876 -145,502 | -45% | -$4.59M |
|
18
Jasper Therapeutics
JSPR
$45.5M
| $4.96M | 2.96% | 218,614 -71,329 | -25% | -$1.62M |
|
19
Trevi Therapeutics
TRVI
$883M
| $4.4M | 2.62% | +1,474,926 | New | +$4.4M |
|
20
Tyra Biosciences
TYRA
$675M
| $4.23M | 2.52% | +264,660 | New | +$4.23M |
|
21
Perspective Therapeutics
CATX
$250M
| $3.95M | 2.35% | +396,242 | New | +$3.95M |
|
22
Black Diamond Therapeutics
BDTX
$157M
| $3.89M | 2.32% | +835,000 | New | +$3.89M |
|
23
Context Therapeutics
CNTX
$75.4M
| $3.78M | 2.25% | 1,886,232 +1,160,281 | +160% | +$2.33M |
|
|
CLYM
24
Climb Bio, Inc. Common Stock
CLYM
$151M
| $3.56M | 2.12% | +500,000 | New | +$3.56M |
|
25
ProMIS Neurosciences
PMN
$28M
| $1.59M | 0.95% | 1,059,582 | – | – |
|